Floatz logo

Fludarabine

Ovarian Adenocarcinoma

TCR2 TherapeuticsSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Ovarian Adenocarcinoma cohort.

Asset / SponsorPhaseRating
IERAMILIMAB
Novartis Pharmaceuticals
Phase 2B
Cyclophosphamide
TCR2 Therapeutics
Phase 1/2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Niraparib
CanariaBio Inc.
Phase 2CCC

View all 15 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →